[go: up one dir, main page]

SE0201661D0 - New salts - Google Patents

New salts

Info

Publication number
SE0201661D0
SE0201661D0 SE0201661A SE0201661A SE0201661D0 SE 0201661 D0 SE0201661 D0 SE 0201661D0 SE 0201661 A SE0201661 A SE 0201661A SE 0201661 A SE0201661 A SE 0201661A SE 0201661 D0 SE0201661 D0 SE 0201661D0
Authority
SE
Sweden
Prior art keywords
acid addition
addition salt
salts
thrombin
new salts
Prior art date
Application number
SE0201661A
Other languages
English (en)
Inventor
Matti Ahlqvist
Martin Bohlin
Tord Inghardt
Anita Lundblad
Carl-Gustaf Sigfridsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0201661A priority Critical patent/SE0201661D0/sv
Publication of SE0201661D0 publication Critical patent/SE0201661D0/sv
Priority to PCT/SE2003/000859 priority patent/WO2003101957A1/en
Priority to EP03728206A priority patent/EP1513806B1/en
Priority to SI200331578T priority patent/SI1513806T1/sl
Priority to HK05105118.1A priority patent/HK1073102B/en
Priority to CA002487509A priority patent/CA2487509A1/en
Priority to ES03728206T priority patent/ES2322048T3/es
Priority to EP09151657A priority patent/EP2055696A1/en
Priority to US10/516,422 priority patent/US7273858B2/en
Priority to PT03728206T priority patent/PT1513806E/pt
Priority to NZ536738A priority patent/NZ536738A/en
Priority to AU2003232871A priority patent/AU2003232871B2/en
Priority to RU2004133388/04A priority patent/RU2345064C2/ru
Priority to AT03728206T priority patent/ATE425963T1/de
Priority to CN200910260483A priority patent/CN101735131A/zh
Priority to PL03373794A priority patent/PL373794A1/xx
Priority to IL16529503A priority patent/IL165295A0/xx
Priority to JP2004509651A priority patent/JP4541140B2/ja
Priority to MXPA04011912A priority patent/MXPA04011912A/es
Priority to KR10-2004-7019439A priority patent/KR20050009726A/ko
Priority to CNA038124912A priority patent/CN1656067A/zh
Priority to UA20041109441A priority patent/UA81246C2/uk
Priority to NZ554323A priority patent/NZ554323A/en
Priority to DE60326720T priority patent/DE60326720D1/de
Priority to DK03728206T priority patent/DK1513806T3/da
Priority to BR0311365-5A priority patent/BR0311365A/pt
Priority to MYPI20031981A priority patent/MY133333A/en
Priority to TW097151265A priority patent/TWI367754B/zh
Priority to TW092114807A priority patent/TWI313173B/zh
Priority to ARP030101935A priority patent/AR039937A1/es
Priority to SA3240440A priority patent/SA03240440B1/ar
Priority to NO20044867A priority patent/NO329064B1/no
Priority to ZA200409228A priority patent/ZA200409228B/en
Priority to IS7598A priority patent/IS7598A/is
Priority to US11/839,842 priority patent/US7763597B2/en
Priority to RU2008127541/04A priority patent/RU2008127541A/ru
Priority to CY20091100535T priority patent/CY1109085T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
SE0201661A 2002-05-31 2002-05-31 New salts SE0201661D0 (sv)

Priority Applications (37)

Application Number Priority Date Filing Date Title
SE0201661A SE0201661D0 (sv) 2002-05-31 2002-05-31 New salts
KR10-2004-7019439A KR20050009726A (ko) 2002-05-31 2003-05-27 신규 염
IL16529503A IL165295A0 (en) 2002-05-31 2003-05-27 Salts of compounds that inhibit thrombin followingadministration to mammalian patients, pharmaceuti cal compositions containing such salts and processes for obtaining them
EP03728206A EP1513806B1 (en) 2002-05-31 2003-05-27 Sulphonic acid salts of mandelic acid derivatives
SI200331578T SI1513806T1 (sl) 2002-05-31 2003-05-27 Sulfonske kislinske soli derivatov mandljeve kisline
HK05105118.1A HK1073102B (en) 2002-05-31 2003-05-27 Sulphonic acid salts of mandelic acid derivatives
CA002487509A CA2487509A1 (en) 2002-05-31 2003-05-27 New salts
ES03728206T ES2322048T3 (es) 2002-05-31 2003-05-27 Sales de acido sulfonico de derivados de acido mandelico.
EP09151657A EP2055696A1 (en) 2002-05-31 2003-05-27 Acid addition salts of mandelic acid derivatives
US10/516,422 US7273858B2 (en) 2002-05-31 2003-05-27 Salts
PT03728206T PT1513806E (pt) 2002-05-31 2003-05-27 Sais de ácido sulfónico de derivados do ácido mandélico
NZ536738A NZ536738A (en) 2002-05-31 2003-05-27 Pharmaceutically-acceptable acid addition salts of certain methoxy- and ethoxy- amidine compounds, pharmaceutical formulations containing such salts and processes for obtaining them
AU2003232871A AU2003232871B2 (en) 2002-05-31 2003-05-27 New salts
RU2004133388/04A RU2345064C2 (ru) 2002-05-31 2003-05-27 Фармацевтически приемлемые соли присоединения сульфоновой кислоты метоксиамидинового соединения и способ их получения
AT03728206T ATE425963T1 (de) 2002-05-31 2003-05-27 Sulfonsauresalze von mandelsaurederivaten
CN200910260483A CN101735131A (zh) 2002-05-31 2003-05-27 新的盐
PL03373794A PL373794A1 (en) 2002-05-31 2003-05-27 New salts
PCT/SE2003/000859 WO2003101957A1 (en) 2002-05-31 2003-05-27 New salts
MXPA04011912A MXPA04011912A (es) 2002-05-31 2003-05-27 Sales nuevas.
JP2004509651A JP4541140B2 (ja) 2002-05-31 2003-05-27 新塩類
BR0311365-5A BR0311365A (pt) 2002-05-31 2003-05-27 Sal de adição de ácido farmaceuticamente aceitável, processo para a preparação de um sal de adição de ácido formulação farmacêutica, uso de um sal de adição de ácido, e, método de tratamento de uma condição onde a inibição da trombina é requerida
CNA038124912A CN1656067A (zh) 2002-05-31 2003-05-27 新的盐
UA20041109441A UA81246C2 (en) 2002-05-31 2003-05-27 Salts of mandelic acid derivatives
NZ554323A NZ554323A (en) 2002-05-31 2003-05-27 Pharmaceutically-acceptable acid addition salts of certain methoxy-and ethoxy-amidine compounds, pharmaceutical formulations containing such salts, and processes for obtaining them
DE60326720T DE60326720D1 (de) 2002-05-31 2003-05-27 Sulfonsäuresalze von Mandelsäurederivaten
DK03728206T DK1513806T3 (da) 2002-05-31 2003-05-27 Sulfonsyresalte af sulfonsyrederivater
MYPI20031981A MY133333A (en) 2002-05-31 2003-05-29 New salts
TW097151265A TWI367754B (en) 2002-05-31 2003-05-30 New carboxamide compound
TW092114807A TWI313173B (en) 2002-05-31 2003-05-30 New salts
ARP030101935A AR039937A1 (es) 2002-05-31 2003-05-30 Derivados de azetidina como inhibidores de tripsina proteasas
SA3240440A SA03240440B1 (ar) 2002-05-31 2003-12-10 أملاح حمض مضافة مقبولة صيدلانيا من مركبات معينة من ميثوكسي methoxy وايثوكسي ethoxy اميدين amidine وعمليات الحصول عليها
NO20044867A NO329064B1 (no) 2002-05-31 2004-11-09 Syreaddisjonssalter, fremstilling av slike, farmasoytiske preparater omfattende slike samt slike forbindelser for behandling av sykdom
ZA200409228A ZA200409228B (en) 2002-05-31 2004-11-17 New salts.
IS7598A IS7598A (is) 2002-05-31 2004-12-15 Ný sölt
US11/839,842 US7763597B2 (en) 2002-05-31 2007-08-16 Salts
RU2008127541/04A RU2008127541A (ru) 2002-05-31 2008-07-09 Новые соли
CY20091100535T CY1109085T1 (el) 2002-05-31 2009-05-20 Νεα αλατα

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0201661A SE0201661D0 (sv) 2002-05-31 2002-05-31 New salts

Publications (1)

Publication Number Publication Date
SE0201661D0 true SE0201661D0 (sv) 2002-05-31

Family

ID=20288039

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0201661A SE0201661D0 (sv) 2002-05-31 2002-05-31 New salts

Country Status (30)

Country Link
US (2) US7273858B2 (sv)
EP (2) EP2055696A1 (sv)
JP (1) JP4541140B2 (sv)
KR (1) KR20050009726A (sv)
CN (2) CN101735131A (sv)
AR (1) AR039937A1 (sv)
AT (1) ATE425963T1 (sv)
AU (1) AU2003232871B2 (sv)
BR (1) BR0311365A (sv)
CA (1) CA2487509A1 (sv)
CY (1) CY1109085T1 (sv)
DE (1) DE60326720D1 (sv)
DK (1) DK1513806T3 (sv)
ES (1) ES2322048T3 (sv)
IL (1) IL165295A0 (sv)
IS (1) IS7598A (sv)
MX (1) MXPA04011912A (sv)
MY (1) MY133333A (sv)
NO (1) NO329064B1 (sv)
NZ (2) NZ554323A (sv)
PL (1) PL373794A1 (sv)
PT (1) PT1513806E (sv)
RU (2) RU2345064C2 (sv)
SA (1) SA03240440B1 (sv)
SE (1) SE0201661D0 (sv)
SI (1) SI1513806T1 (sv)
TW (2) TWI367754B (sv)
UA (1) UA81246C2 (sv)
WO (1) WO2003101957A1 (sv)
ZA (1) ZA200409228B (sv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201661D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2005097804A1 (en) * 2004-04-09 2005-10-20 Hanmi Pharm. Co., Ltd. Crystalline clopidogrel naphthalenesulfonate or hydrate thereof, method for preparing same and pharmaceutical composition containing same
MXPA06012128A (es) * 2004-04-20 2007-01-31 Sanofi Aventis Sal de clopidogrel y formas polimorfas de la misma.
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
TW200900033A (en) * 2007-06-21 2009-01-01 Wen-Qing Li Automatic brewing machine
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
JPS57149217A (en) 1981-03-11 1982-09-14 Kaken Pharmaceut Co Ltd Slow-releasing pharmaceutical preparation
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
IL77748A (en) 1985-02-04 1991-11-21 Merrell Dow Pharma Amino acid and peptide derivatives as peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
IT1229491B (it) 1988-12-28 1991-09-03 Roussel Maestretti S P A Ora R Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
TW201303B (sv) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
ZA928581B (en) 1991-11-12 1994-05-06 Lilly Co Eli Antithrombotic agents
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
ES2110599T3 (es) 1992-03-04 1998-02-16 Gyogyszerkutato Intezet Nuevos derivados de peptidos anticoagulantes y composiciones farmaceuticas que contienen los mismos, asi como un proceso para su preparacion.
TW223629B (sv) 1992-03-06 1994-05-11 Hoffmann La Roche
SE9301912D0 (sv) 1993-06-03 1993-06-03 Ab Astra Process for the production of aminoalkylguandines
US6984627B1 (en) * 1993-06-03 2006-01-10 Astrazeneca Ab Peptide derivatives
US5783563A (en) * 1993-06-03 1998-07-21 Astra Aktiebolag Method for treatment or prophylaxis of venous thrombosis
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
AU1025795A (en) * 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
ZA951617B (en) 1994-03-04 1997-02-27 Lilly Co Eli Antithrombotic agents.
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5498724A (en) * 1994-06-28 1996-03-12 Aktiebolaget Astra Pyrazoleamidine compounds
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
WO1996025426A1 (de) * 1995-02-17 1996-08-22 Basf Aktiengesellschaft Neue dipeptidische amidine als thrombin-inhibitoren
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US6083532A (en) 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5695781A (en) 1995-03-01 1997-12-09 Hallmark Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers
JPH11503161A (ja) 1995-04-04 1999-03-23 メルク エンド カンパニー インコーポレーテッド トロンビン阻害剤
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
AR005245A1 (es) * 1995-12-21 1999-04-28 Astrazeneca Ab Prodrogas de inhibidores de trombina, una formulación farmaceutica que las comprende, el uso de dichas prodrogas para la manufactura de un medicamento y un procedimiento para su preparacion
SE9601556D0 (sv) 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
JP2000514788A (ja) 1996-06-25 2000-11-07 イーライ・リリー・アンド・カンパニー 抗凝固剤
SE9602646D0 (sv) * 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
SE9603724D0 (sv) 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
IT1297461B1 (it) 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
US6174913B1 (en) * 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9802974D0 (sv) * 1998-09-03 1998-09-03 Astra Ab New crystalline forms
US6331309B1 (en) 1998-09-04 2001-12-18 Scios Inc. Hydrogel compositions for the controlled release administration of growth factors
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
CA2355792A1 (en) * 1999-01-13 2000-07-20 Astrazeneca Ab New amidinobenzylamine derivatives and their use as thrombin inhibitors
SE9902550D0 (sv) 1999-07-02 1999-07-02 Astra Ab New crystalline forms
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
AU8039501A (en) 2000-08-16 2002-02-25 Astrazeneca Ab New amidino derivatives and their use as thrombin inhibitors
US6433186B1 (en) * 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
SE0003125D0 (sv) 2000-09-05 2000-09-05 Astrazeneca Ab Modified polymers
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
SE0102921D0 (sv) * 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US6287599B1 (en) 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA78195C2 (uk) 2001-08-30 2007-03-15 Astrazeneca Ab Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі
US6811794B2 (en) 2001-12-20 2004-11-02 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201658D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
SE0303220D0 (sv) 2003-11-28 2003-11-28 Astrazeneca Ab New process
GB0503672D0 (en) 2005-02-23 2005-03-30 Astrazeneca Ab New process
GB0510546D0 (en) 2005-05-24 2005-06-29 Astrazeneca Ab New process
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms

Also Published As

Publication number Publication date
US20050234035A1 (en) 2005-10-20
NZ536738A (en) 2007-05-31
AU2003232871B2 (en) 2010-08-19
RU2345064C2 (ru) 2009-01-27
SI1513806T1 (sl) 2009-06-30
EP2055696A1 (en) 2009-05-06
DE60326720D1 (de) 2009-04-30
US7273858B2 (en) 2007-09-25
CN1656067A (zh) 2005-08-17
RU2008127541A (ru) 2010-01-20
ZA200409228B (en) 2005-05-17
CN101735131A (zh) 2010-06-16
NO20044867L (no) 2004-12-23
BR0311365A (pt) 2005-03-01
ATE425963T1 (de) 2009-04-15
NZ554323A (en) 2008-10-31
EP1513806B1 (en) 2009-03-18
KR20050009726A (ko) 2005-01-25
IS7598A (is) 2004-12-15
WO2003101957A1 (en) 2003-12-11
DK1513806T3 (da) 2009-06-15
CY1109085T1 (el) 2012-05-23
IL165295A0 (en) 2005-12-18
JP2005532346A (ja) 2005-10-27
TWI367754B (en) 2012-07-11
RU2004133388A (ru) 2005-07-10
TWI313173B (en) 2009-08-11
AU2003232871A1 (en) 2003-12-19
TW200927094A (en) 2009-07-01
MXPA04011912A (es) 2005-03-31
HK1073102A1 (en) 2005-09-23
TW200402293A (en) 2004-02-16
AR039937A1 (es) 2005-03-09
PT1513806E (pt) 2009-05-04
NO329064B1 (no) 2010-08-09
PL373794A1 (en) 2005-09-19
UA81246C2 (en) 2007-12-25
EP1513806A1 (en) 2005-03-16
ES2322048T3 (es) 2009-06-16
US20080269176A1 (en) 2008-10-30
US7763597B2 (en) 2010-07-27
JP4541140B2 (ja) 2010-09-08
CA2487509A1 (en) 2003-12-11
MY133333A (en) 2007-11-30
SA03240440B1 (ar) 2008-02-24

Similar Documents

Publication Publication Date Title
SE0100902D0 (sv) Compounds
DK1063230T3 (da) Cykliske aminoforbindelser
DE69809187D1 (de) Metalloproteinase-Inhibitoren
AR029696A1 (es) Derivados de ciclopentil-glutaramida como inhibidores de endopeptidasa neutra
DK1120388T3 (da) Anvendelse af pyrazolderivater som nitrifikationsinhibitor
ATE431827T1 (de) Phosphonocephem-verbindung
CY1109085T1 (el) Νεα αλατα
ATE457025T1 (de) Kinaseinhibitoren
EP1314712A4 (en) NF-KAPPA-B INHIBITOR CONTAINING SUBSTITUTED BENZOIC ACID DERIVATIVE AS ACTIVE INGREDIENT
NO20012914D0 (no) Nye amidinoderivater og deres anvendelse som trombininhibitorer
DK1554285T3 (da) Kemisk mellemprodukt
SE0102921D0 (sv) Pharmaceutically useful compounds
DK1311480T3 (da) Nye amidinoderivater og deres anvendelse som thrambininhibitor
NO20040813L (no) Nye mandelsyre derivater og anvendelse derav som trombin inhibitorer.
DK1660471T3 (da) Derivater af hydroxamsyre som metalloproteinaseinhibitorer
DK1637141T3 (da) Stabiliseret proteasesammensætning omfattende en serinprotease, morpholinderivater og reversible inhibitorer af serinproteasen
DE602005010369D1 (de) 2-thiaquinolizidines als Glycosidase- und Glycosyltransferase-Inhibitoren
UY28102A1 (es) Nuevas sales
TWI264434B (en) New mandelic acid derivatives and their use as thrombin inhibitors
TH98266A (th) เกลือชนิดใหม่
SE0403072D0 (sv) Pharmaceutically useful salts of carboxylic acid derivates
SE0201005D0 (sv) New Process
TH36520A (th) อนุพันธ์อะมิดิโนชนิดใหม่และการใช้สารเหล่านั้นเป็นตัวยับยั้งธรอมบิน